The association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: a meta-analysis based on case–control studies

The apurinic/apyrimidinic endonuclease 1 (APE1) plays important roles in the repair of DNA damage and adducts. However, previous case–control studies on the association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility have shown contradictory results, this meta-analysis was performed to draw a more precise estimation of the relationship. A total of seven case–control studies including 1,294 cases and 1,762 controls were included for analysis. In overall, no significant associations were found in all genetic models (GG vs. TT: OR = 1.16, 95 % CI 0.89–1.52; TG vs. TT: OR = 1.04, 95 % CI 0.81–1.35; the dominant model GG + TG vs. TT: OR = 1.12, 95 % CI 0.96–1.30; the recessive model GG vs. TG + TT: OR = 0.90, 95 % CI 0.77–1.04); in the subgroup by source of control, we found a significant association for the dominant model in Hospital-based subgroup (OR = 1.34, 95 % CI 1.08–1.68), no significant associations were found in other models in the subgroups. This meta-analysis suggested that the APE1 Asp148Glu polymorphism was a risk factor for prostate cancer susceptibility in Hospital-based population.